BioGaia AB (publ) (BIOGY) Stock

About BioGaia AB (publ)

BioGaia AB (publ) is a global enterprise dedicated to the development, marketing, and sale of probiotic products, all backed by documented health benefits. The company organizes its activities into three primary divisions: Pediatrics, Adult Health, and 'Other'. Within the Pediatric segment, BioGaia provides items such as liquid drops, oral rehydration solutions, and gut health tablets, alongside supplying probiotic cultures for integration into infant formula. The Adult Health segment offers both digestive health tablets and oral hygiene lozenges, as well as providing cultures that are incorporated into dairy products by its licensees. The 'Other' segment focuses on delivering packaging solutions. BioGaia's product portfolio addresses a wide array of health conditions, including infantile colic and digestive problems in children, acute and antibiotic-associated diarrhea, gingivitis, periodontal disease, general wellness, Helicobacter pylori infections (the bacterium causing gastric ulcers), and low bone density. All of the company's products are sold under the BioGaia brand. Founded in 1990, BioGaia AB (publ) is headquartered in Stockholm, Sweden.

BioGaia AB (publ) is headquartered in SE.

BioGaia AB (publ) (BIOGY) stock trades at $11.00 with a market capitalization of $1.11B. The stock is valued at a price-to-earnings (P/E) ratio of 33.70, price-to-book of 10.62, price-to-sales of 7.20. Over the past 52 weeks the stock has ranged between $8.79 and $11.46, and currently trades 4.0% below its 52-week high. It pays a dividend yielding 3.82%.

On profitability, BioGaia AB (publ) generates a return on equity (ROE) of 27.58% — well above the market average, a sign of a high-quality business, return on capital employed of 38.89%, an operating margin of 27.67%, a net profit margin of 21.97%.

Official website: www.biogaiagroup.com